Millennium Management’s BridgeBio Pharma BBIO Stock Holding History

Millennium Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.3M	Sell	487,594 -145,689	-23%	-$10.2M	0.01%	1119
2026 Q1	$47M	Buy	633,283 +596,698	+1,631%	+$43.3M	0.02%	863
2025 Q4	$2.8M	Sell	36,585 -133,852	-79%	-$8.79M	﹤0.01%	3633
2025 Q3	$8.85M	Sell	170,437 -450,021	-73%	-$21.9M	﹤0.01%	2514
2025 Q2	$26.8M	Buy	620,458 +380,538	+159%	+$13.8M	0.01%	1307
2025 Q1	$8.29M	Buy	239,920 +128,849	+116%	+$4.34M	﹤0.01%	2376
2024 Q4	$3.05M	Buy	111,071 +73,599	+196%	+$1.9M	﹤0.01%	3291
2024 Q3	$954K	Sell	37,472 -204,308	-85%	-$5.36M	﹤0.01%	4318
2024 Q2	$6.12M	Buy	241,780 +125,178	+107%	+$3.42M	﹤0.01%	2530
2024 Q1	$3.61M	Buy	116,602 +60,839	+109%	+$2.07M	﹤0.01%	3208
2023 Q4	$2.25M	Sell	55,763 -410,291	-88%	-$12.3M	﹤0.01%	3506
2023 Q3	$12.3M	Buy	+466,054	New	+$13.2M	0.01%	1859
2023 Q2	–	Sell	-310,569	Closed	-$4.67M	–	6110
2023 Q1	$5.15M	Buy	310,569 +226,392	+269%	+$2.64M	﹤0.01%	2581
2022 Q4	$641K	Sell	84,177 -1,081,131	-93%	-$10.4M	﹤0.01%	4548
2022 Q3	$11.6M	Buy	1,165,308 +563,441	+94%	+$5.85M	0.01%	1958
2022 Q2	$5.46M	Sell	601,867 -315,942	-34%	-$2.64M	﹤0.01%	2705
2022 Q1	$9.32M	Sell	917,809 -578,264	-39%	-$5.93M	﹤0.01%	2239
2021 Q4	$25M	Buy	1,496,073 +1,258,858	+531%	+$53.3M	0.01%	1246
2021 Q3	$11.1M	Buy	237,215 +96,204	+68%	+$5.16M	0.01%	1918
2021 Q2	$8.6M	Buy	141,011 +99,169	+237%	+$5.66M	0.01%	2101
2021 Q1	$2.58M	Sell	41,842 -51,600	-55%	-$3.38M	﹤0.01%	3281
2020 Q4	$6.64M	Buy	+93,442	New	+$4.51M	﹤0.01%	2170
2020 Q3	–	Sell	-39,680	Closed	-$1.29M	–	4439
2020 Q2	$1.29M	Sell	39,680 -196,520	-83%	-$5.99M	﹤0.01%	2834
2020 Q1	$6.85M	Buy	+236,200	New	+$7.32M	0.02%	1108
2019 Q4	–	Sell	-37,382	Closed	-$802K	–	4199
2019 Q3	$802K	Sell	37,382 -342,537	-90%	-$9.48M	﹤0.01%	2975
2019 Q2	$10.2M	Buy	+379,919	New	+$10.4M	0.02%	1231

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Millennium Management's BBIO Position: Q2 2026 in Review

Millennium Management reduced its BridgeBio Pharma (BBIO) stake by 23% in Q2 2026, selling an estimated $10.2M and leaving 487,594 shares worth $36.3M. The position accounts for 0.01% of the portfolio, ranked #1119.

Millennium Management first reported a position in BBIO in Q2 2019 and has held it in 26 quarters since. The position peaked at $47M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Millennium Management held 487,594 shares of BridgeBio Pharma worth $36.3M as of Q2 2026.
Millennium Management sold 145,689 BridgeBio Pharma shares in Q2 2026, an estimated $10.2M.
BridgeBio Pharma made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1119 holding.
Millennium Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 26 quarters since.
Millennium Management's BridgeBio Pharma position peaked at $47M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.